Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—“Yes”

Detalles Bibliográficos
Autores principales: Rolfes, Leoni, Meuth, Sven G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Controversies in Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978458/
https://www.ncbi.nlm.nih.gov/pubmed/34931903
http://dx.doi.org/10.1177/13524585211055593
_version_ 1784680967421558784
author Rolfes, Leoni
Meuth, Sven G
author_facet Rolfes, Leoni
Meuth, Sven G
author_sort Rolfes, Leoni
collection PubMed
description
format Online
Article
Text
id pubmed-8978458
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-89784582022-04-05 Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—“Yes” Rolfes, Leoni Meuth, Sven G Mult Scler Controversies in Multiple Sclerosis SAGE Publications 2021-12-21 2022-04 /pmc/articles/PMC8978458/ /pubmed/34931903 http://dx.doi.org/10.1177/13524585211055593 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Controversies in Multiple Sclerosis
Rolfes, Leoni
Meuth, Sven G
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—“Yes”
title Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—“Yes”
title_full Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—“Yes”
title_fullStr Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—“Yes”
title_full_unstemmed Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—“Yes”
title_short Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—“Yes”
title_sort stable multiple sclerosis patients on anti-cd20 therapy should go on extended interval dosing—“yes”
topic Controversies in Multiple Sclerosis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978458/
https://www.ncbi.nlm.nih.gov/pubmed/34931903
http://dx.doi.org/10.1177/13524585211055593
work_keys_str_mv AT rolfesleoni stablemultiplesclerosispatientsonanticd20therapyshouldgoonextendedintervaldosingyes
AT meuthsveng stablemultiplesclerosispatientsonanticd20therapyshouldgoonextendedintervaldosingyes

Ejemplares similares